Anonymous
Guest
Anonymous
Guest
Vertex Pharmaceuticals is galloping ahead with its hepatitis C drug Incivek. So fast, in fact, that at least one analyst thinks the breakthrough treatment could top $1 billion this year, Forbes reports. And that's with only 222 days on the market.
http://www.fiercepharma.com/story/vertexs-incivek-could-top-1b-year-analyst-says/2011-08-19
More layoffs around the corner.
http://www.fiercepharma.com/story/vertexs-incivek-could-top-1b-year-analyst-says/2011-08-19
More layoffs around the corner.